The aim of the fund is to achieve long term growth from investments principally in European equities, excluding the UK.
Name | % Net Assets |
---|---|
Roche | 4.0% |
Novartis | 3.7% |
BNP Paribas | 3.1% |
Novo-Nordisk | 3.0% |
Telefónica | 2.6% |
Allianz SE | 2.6% |
Nordea Bank | 2.5% |
SAP | 2.4% |
Ericsson | 2.4% |
Banco Bilbao Vizcaya Argentaria | 2.3% |
Key | % Net Assets |
---|---|
Roche | 4.0% |
Novartis | 3.7% |
BNP Paribas | 3.1% |
Novo-Nordisk | 3.0% |
Other | 86.2% |
Date | 03-Apr-2024 |
---|---|
NAV | 155.59p |
Currency | GBP |
Change | -1.47p |
% | -0.94% |
YTD change | 12.04p |
YTD % | 8.39% |
Fund Inception | 28/10/2011 |
---|---|
Fund Manager | Mark Page / Laurent Millet |
TER | 1.50 (30-Apr-2012) |
Minimum Investment | |
---|---|
Initial | £250000 |
Additional | n/a |
Savings | n/a |
Charges | |
---|---|
Initial | 1.00% |
Annual Mang't | 0.75% |
Exit | n/a |
Name | % |
---|---|
No risk data available. |
You are here: research